Biomotion Technologies is a producer of 3D bioprinting systems. Our devices allow the layer-by-layer deposition of cells and cell-laden biomaterials to produce organotypical 3D tissue systems for drug testing and personalized implant purposes. Tissue engineering companies run into a large problem when scaling their tissue production due to low production reproducibility, citing up to 20% weight variation of the produced tissue and uneven cell distribution. This leads to a large number of rejects and a challenging regulatory approval. We solve this production problem with our bioprinters with a built-in quality assurance system. Our bioprinters constantly supervise their bioprinting process in-line. When the printer detects a process variation outside of the set tolerance, it will automatically adjust printing parameters in real-time so that a potential defect is instantly correct. This way, we can guarantee the reproducible production of 3D tissues, regardless of the batch. Our system also delivers the required production data for the medical dossier of Tissue engineered medical products (TEMPs) according to ISO/TS 21560. Our device lifts 3D tissue models from the R&D stage into a production stage, thereby enabling scalable fabrication